Skip to main content
Erschienen in: Current Oncology Reports 3/2012

01.06.2012 | Gastrointestinal Cancers (L Saltz, Section Editor)

Toward the Non-surgical Management of Locally Advanced Rectal Cancer

verfasst von: Alice Dewdney, David Cunningham

Erschienen in: Current Oncology Reports | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Neoadjuvant short-course radiotherapy and long-course chemoradiation (CRT) reduce local recurrence rates when compared to surgery alone and remain widely accepted as standard of care for patients with locally advanced rectal cancer. However, surgery is not without complications and a non-surgical approach in carefully selected patients warrants evaluation. A pathological complete response to CRT is associated with a significant improvement in survival and it has been suggested that a longer time interval between the completion of CRT and surgery increases tumor downstaging. Intensification of neoadjuvant treatment regimens to increase tumor downstaging has been evaluated in a number of clinical trials and more recently the introduction of neoadjuvant chemotherapy prior to CRT has demonstrated high rates of radiological tumor regression. Careful selection of patients using high-resolution MRI may allow a non-surgical approach in a subgroup of patients achieving a complete response to neoadjuvant therapies after an adequate time period. Clearly this needs prospective evaluation within a clinical trial setting, incorporating modern imaging techniques, and tissue biomarkers to allow accurate prediction and assessment of response.
Literatur
2.
Zurück zum Zitat Kikuchi R, et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. Dis Colon Rectum. 1995;38(12):1286–95.PubMedCrossRef Kikuchi R, et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. Dis Colon Rectum. 1995;38(12):1286–95.PubMedCrossRef
3.
Zurück zum Zitat Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol. 2007;25(8):1014–20.PubMedCrossRef Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol. 2007;25(8):1014–20.PubMedCrossRef
4.
Zurück zum Zitat Peng J, et al. Long-term outcome of early-stage rectal cancer undergoing standard resection and local excision. Clin Colorectal Cancer. 2011;10(1):37–41.PubMed Peng J, et al. Long-term outcome of early-stage rectal cancer undergoing standard resection and local excision. Clin Colorectal Cancer. 2011;10(1):37–41.PubMed
5.
Zurück zum Zitat Paty PB, et al. Long-term results of local excision for rectal cancer. Ann Surg. 2002;236(4):522–9. discussion 529–30.PubMedCrossRef Paty PB, et al. Long-term results of local excision for rectal cancer. Ann Surg. 2002;236(4):522–9. discussion 529–30.PubMedCrossRef
6.
Zurück zum Zitat Gopaul D, et al. Outcome of local excision of rectal carcinoma. Dis Colon Rectum. 2004;47(11):1780–8.PubMedCrossRef Gopaul D, et al. Outcome of local excision of rectal carcinoma. Dis Colon Rectum. 2004;47(11):1780–8.PubMedCrossRef
7.
Zurück zum Zitat Lamont JP, et al. Should locally excised T1 rectal cancer receive adjuvant chemoradiation? Am J Surg. 2000;180(6):402–5. discussion 405–6.PubMedCrossRef Lamont JP, et al. Should locally excised T1 rectal cancer receive adjuvant chemoradiation? Am J Surg. 2000;180(6):402–5. discussion 405–6.PubMedCrossRef
8.
Zurück zum Zitat Varma MG, et al. Local excision of rectal carcinoma. Arch Surg. 1999;134(8):863–7. discussion 867–8.PubMedCrossRef Varma MG, et al. Local excision of rectal carcinoma. Arch Surg. 1999;134(8):863–7. discussion 867–8.PubMedCrossRef
9.
Zurück zum Zitat • Heald RJ. Total mesorectal excision is optimal surgery for rectal cancer: a Scandinavian consensus. Br J Surg. 1995;82(10):1297–9. Demonstrated that total mesorectal excision reduced local recurrence rates when compared to conventional surgery; TME surgery is now standard of care.PubMedCrossRef • Heald RJ. Total mesorectal excision is optimal surgery for rectal cancer: a Scandinavian consensus. Br J Surg. 1995;82(10):1297–9. Demonstrated that total mesorectal excision reduced local recurrence rates when compared to conventional surgery; TME surgery is now standard of care.PubMedCrossRef
10.
Zurück zum Zitat Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1(8496):1479–82.PubMedCrossRef Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1(8496):1479–82.PubMedCrossRef
11.
Zurück zum Zitat Nugent KP, et al. Quality of life in stoma patients. Dis Colon Rectum. 1999;42(12):1569–74.PubMedCrossRef Nugent KP, et al. Quality of life in stoma patients. Dis Colon Rectum. 1999;42(12):1569–74.PubMedCrossRef
12.
Zurück zum Zitat Enker WE, et al. Safety and efficacy of low anterior resection for rectal cancer: 681 consecutive cases from a specialty service. Ann Surg. 1999;230(4):544–52. discussion 552–4.PubMedCrossRef Enker WE, et al. Safety and efficacy of low anterior resection for rectal cancer: 681 consecutive cases from a specialty service. Ann Surg. 1999;230(4):544–52. discussion 552–4.PubMedCrossRef
13.
Zurück zum Zitat Camilleri-Brennan J, Steele RJ. Prospective analysis of quality of life and survival following mesorectal excision for rectal cancer. Br J Surg. 2001;88(12):1617–22.PubMedCrossRef Camilleri-Brennan J, Steele RJ. Prospective analysis of quality of life and survival following mesorectal excision for rectal cancer. Br J Surg. 2001;88(12):1617–22.PubMedCrossRef
14.
Zurück zum Zitat Nesbakken A, et al. Bladder and sexual dysfunction after mesorectal excision for rectal cancer. Br J Surg. 2000;87(2):206–10.PubMedCrossRef Nesbakken A, et al. Bladder and sexual dysfunction after mesorectal excision for rectal cancer. Br J Surg. 2000;87(2):206–10.PubMedCrossRef
15.
Zurück zum Zitat • Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26(2):303–12. Demonstrated that histological involvement of the circumferential margin predicts for higher rates of local recurrence and distant metastases.PubMedCrossRef • Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26(2):303–12. Demonstrated that histological involvement of the circumferential margin predicts for higher rates of local recurrence and distant metastases.PubMedCrossRef
16.
Zurück zum Zitat Smith NJ, et al. MRI for detection of extramural vascular invasion in rectal cancer. AJR Am J Roentgenol. 2008;191(5):1517–22.PubMedCrossRef Smith NJ, et al. MRI for detection of extramural vascular invasion in rectal cancer. AJR Am J Roentgenol. 2008;191(5):1517–22.PubMedCrossRef
17.
Zurück zum Zitat Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology. 2007;243(1):132–9. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology. 2007;243(1):132–9.
18.
Zurück zum Zitat Gunderson LL, et al. Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol. 2010;28(2):256–63.PubMedCrossRef Gunderson LL, et al. Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol. 2010;28(2):256–63.PubMedCrossRef
19.
Zurück zum Zitat Nagtegaal ID, et al. Low rectal cancer: a call for a change of approach in abdominoperineal resection. J Clin Oncol. 2005;23(36):9257–64.PubMedCrossRef Nagtegaal ID, et al. Low rectal cancer: a call for a change of approach in abdominoperineal resection. J Clin Oncol. 2005;23(36):9257–64.PubMedCrossRef
20.
Zurück zum Zitat • Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med. 1997;336(14):980–7. Demonstrated that preoperative short-course radiotherapy reduces local recurrence when compared to surgery alone and resulted in an improvement in overall survival. This is the only trial of preoperative radiotherapy to demonstrate a survival benefit. • Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med. 1997;336(14):980–7. Demonstrated that preoperative short-course radiotherapy reduces local recurrence when compared to surgery alone and resulted in an improvement in overall survival. This is the only trial of preoperative radiotherapy to demonstrate a survival benefit.
21.
Zurück zum Zitat • Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40. Demonstrated that preoperative chemoradiotherapy reduced local recurrence when compared to postoperative radiotherapy.PubMedCrossRef • Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40. Demonstrated that preoperative chemoradiotherapy reduced local recurrence when compared to postoperative radiotherapy.PubMedCrossRef
22.
Zurück zum Zitat Bujko K, Nowacki M, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Brit J Surg. 2006;93:1215–23. Bujko K, Nowacki M, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Brit J Surg. 2006;93:1215–23.
23.
Zurück zum Zitat Mohiuddin M, et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol. 2006;24(4):650–5.PubMedCrossRef Mohiuddin M, et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol. 2006;24(4):650–5.PubMedCrossRef
24.
Zurück zum Zitat Rodel C, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23(34):8688–96.PubMedCrossRef Rodel C, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23(34):8688–96.PubMedCrossRef
25.
Zurück zum Zitat Diaz-Gonzalez JA, et al. Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation. Int J Radiat Oncol Biol Phys. 2006;64(4):1122–8.PubMedCrossRef Diaz-Gonzalez JA, et al. Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation. Int J Radiat Oncol Biol Phys. 2006;64(4):1122–8.PubMedCrossRef
26.
Zurück zum Zitat Maas M, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–44.PubMedCrossRef Maas M, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–44.PubMedCrossRef
27.
Zurück zum Zitat Folkesson J, et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23(24):5644–50.PubMedCrossRef Folkesson J, et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23(24):5644–50.PubMedCrossRef
28.
Zurück zum Zitat Kapiteijn E, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46.PubMedCrossRef Kapiteijn E, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46.PubMedCrossRef
29.
Zurück zum Zitat Bosset JF, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–23.PubMedCrossRef Bosset JF, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–23.PubMedCrossRef
30.
Zurück zum Zitat Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2011. J Clin Oncol 29:2011 (suppl; abstr 3516). Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2011. J Clin Oncol 29:2011 (suppl; abstr 3516).
31.
Zurück zum Zitat Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet. 2001;358(9290):1291–304. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet. 2001;358(9290):1291–304.
32.
Zurück zum Zitat Francois Y, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17(8):2396.PubMed Francois Y, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17(8):2396.PubMed
33.
Zurück zum Zitat Tulchinsky H, et al. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol. 2008;15(10):2661–7.PubMedCrossRef Tulchinsky H, et al. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol. 2008;15(10):2661–7.PubMedCrossRef
34.
Zurück zum Zitat Habr-Gama A, et al. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys. 2008;71(4):1181–8.PubMedCrossRef Habr-Gama A, et al. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys. 2008;71(4):1181–8.PubMedCrossRef
35.
Zurück zum Zitat Habr-Gama A, et al. Preoperative chemoradiation therapy for low rectal cancer. Impact on downstaging and sphincter-saving operations. Hepatogastroenterology. 2004;51(60):1703–7.PubMed Habr-Gama A, et al. Preoperative chemoradiation therapy for low rectal cancer. Impact on downstaging and sphincter-saving operations. Hepatogastroenterology. 2004;51(60):1703–7.PubMed
36.
Zurück zum Zitat Habr-Gama A, et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg. 2006;10(10):1319–28. discussion 1328–9.PubMedCrossRef Habr-Gama A, et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg. 2006;10(10):1319–28. discussion 1328–9.PubMedCrossRef
37.
Zurück zum Zitat Maas M, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011. Maas M, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011.
38.
Zurück zum Zitat Yu S, Brown G, Chua S, et al. Update in deferral of rectal surgery following a continued response to preoperative chemoradiotherapy study: a Phase II Multicentre Study in United Kingdom. J Clin Oncol. 2011;29:(suppl 4; abstr 489), 2011. Yu S, Brown G, Chua S, et al. Update in deferral of rectal surgery following a continued response to preoperative chemoradiotherapy study: a Phase II Multicentre Study in United Kingdom. J Clin Oncol. 2011;29:(suppl 4; abstr 489), 2011.
39.
Zurück zum Zitat Movsas B, et al. Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer. Am J Clin Oncol. 2006;29(5):435–41.PubMedCrossRef Movsas B, et al. Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer. Am J Clin Oncol. 2006;29(5):435–41.PubMedCrossRef
40.
Zurück zum Zitat Wiltshire KL, et al. Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival. Int J Radiat Oncol Biol Phys. 2006;64(3):709–16.PubMedCrossRef Wiltshire KL, et al. Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival. Int J Radiat Oncol Biol Phys. 2006;64(3):709–16.PubMedCrossRef
41.
Zurück zum Zitat Patel C, Kattepogu K, Park I, et al. Impact of preoperative radiation dose escalation on pathologic outcomes and radiation toxicity in locally advanced rectal cancer (LARC): a matched-pair analysis. J Clin Oncol. 2011;29 (suppl; abstr e14036) 2011. Patel C, Kattepogu K, Park I, et al. Impact of preoperative radiation dose escalation on pathologic outcomes and radiation toxicity in locally advanced rectal cancer (LARC): a matched-pair analysis. J Clin Oncol. 2011;29 (suppl; abstr e14036) 2011.
42.
Zurück zum Zitat Mohiuddin M, et al. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys. 2000;48(4):1075–80.PubMedCrossRef Mohiuddin M, et al. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys. 2000;48(4):1075–80.PubMedCrossRef
43.
Zurück zum Zitat Papillon J, Gerard JP. Role of radiotherapy in anal preservation for cancers of the lower third of the rectum. Int J Radiat Oncol Biol Phys. 1990;19(5):1219–20.PubMedCrossRef Papillon J, Gerard JP. Role of radiotherapy in anal preservation for cancers of the lower third of the rectum. Int J Radiat Oncol Biol Phys. 1990;19(5):1219–20.PubMedCrossRef
44.
Zurück zum Zitat Gerard JP, Romestaing P, Chapet O. Radiotherapy alone in the curative treatment of rectal carcinoma. Lancet Oncol. 2003;4(3):158–66.PubMedCrossRef Gerard JP, Romestaing P, Chapet O. Radiotherapy alone in the curative treatment of rectal carcinoma. Lancet Oncol. 2003;4(3):158–66.PubMedCrossRef
45.
Zurück zum Zitat Gerard JP, et al. Long-term control of T2-T3 rectal adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys. 2002;54(1):142–9.PubMedCrossRef Gerard JP, et al. Long-term control of T2-T3 rectal adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys. 2002;54(1):142–9.PubMedCrossRef
46.
Zurück zum Zitat Jakobsen A, et al. Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost. Int J Radiat Oncol Biol Phys. 2006;64(2):461–5.PubMedCrossRef Jakobsen A, et al. Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost. Int J Radiat Oncol Biol Phys. 2006;64(2):461–5.PubMedCrossRef
47.
Zurück zum Zitat Jakobsen A, Appelt A, Lindebjerg J, et al. The dose-effect relationship in preoperative chemoradiation of locally advanced rectal cancer: preliminary results of a phase III trial. J Clin Oncol. 2011. J Clin Oncol 29: 2011 (suppl; abstr 3512). Jakobsen A, Appelt A, Lindebjerg J, et al. The dose-effect relationship in preoperative chemoradiation of locally advanced rectal cancer: preliminary results of a phase III trial. J Clin Oncol. 2011. J Clin Oncol 29: 2011 (suppl; abstr 3512).
48.
Zurück zum Zitat Arbea L, et al. Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol. 2010;5:17.PubMedCrossRef Arbea L, et al. Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol. 2010;5:17.PubMedCrossRef
49.
Zurück zum Zitat Callister M, Ezzell G, Gunderson L. IMRT reduces the dose to small bowel and other pelvic organs in the preoperative treatment of rectal cancer. Int J Radiat Oncol Biol Phys. 2006;66(3):S290.CrossRef Callister M, Ezzell G, Gunderson L. IMRT reduces the dose to small bowel and other pelvic organs in the preoperative treatment of rectal cancer. Int J Radiat Oncol Biol Phys. 2006;66(3):S290.CrossRef
50.
Zurück zum Zitat Samuelian JM, et al. Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2011. Samuelian JM, et al. Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2011.
51.
Zurück zum Zitat Garofalo M, Moughan J, Hong T, et al. RTOG 0822: a Phase II study of Preoperative (PREOP) Chemoradiotherapy (CRT) utilizing IMRT in combination with Capecitabine (C) and Oxaliplatin (O) for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2011;81(2 Suppl):S3–S4. Garofalo M, Moughan J, Hong T, et al. RTOG 0822: a Phase II study of Preoperative (PREOP) Chemoradiotherapy (CRT) utilizing IMRT in combination with Capecitabine (C) and Oxaliplatin (O) for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2011;81(2 Suppl):S3–S4.
52.
Zurück zum Zitat Jingu K, et al. Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP. BMC Cancer. 2010;10:127.PubMedCrossRef Jingu K, et al. Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP. BMC Cancer. 2010;10:127.PubMedCrossRef
53.
Zurück zum Zitat Aschele C, et al. A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Proc Am Soc Clin Oncol. 2002;21:132a. Aschele C, et al. A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Proc Am Soc Clin Oncol. 2002;21:132a.
54.
Zurück zum Zitat Carraro S, et al. Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study. Int J Radiat Oncol Biol Phys. 2002;54(2):397–402.PubMedCrossRef Carraro S, et al. Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study. Int J Radiat Oncol Biol Phys. 2002;54(2):397–402.PubMedCrossRef
55.
Zurück zum Zitat Gerard JP, et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol. 2003;21(6):1119–24.PubMedCrossRef Gerard JP, et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol. 2003;21(6):1119–24.PubMedCrossRef
56.
Zurück zum Zitat Sebag-Montefiore D, et al. Preoperative radiation and oxaliplatin in combination with 5-fluorouracil and low-dose leucovorin in locally advanced rectal cancer. Proc Am Soc Clin Oncol. 2002;21:146a. Sebag-Montefiore D, et al. Preoperative radiation and oxaliplatin in combination with 5-fluorouracil and low-dose leucovorin in locally advanced rectal cancer. Proc Am Soc Clin Oncol. 2002;21:146a.
57.
Zurück zum Zitat Gerard JP, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28(10):1638–44.PubMedCrossRef Gerard JP, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28(10):1638–44.PubMedCrossRef
58.
Zurück zum Zitat Aschele C, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 Randomized Phase III Trial. J Clin Oncol. 2011;29(20):2773–80.PubMedCrossRef Aschele C, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 Randomized Phase III Trial. J Clin Oncol. 2011;29(20):2773–80.PubMedCrossRef
59.
Zurück zum Zitat Roh M, Yothers G, O’Connell M, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol. 2011. J Clin Oncol 29:2011 (suppl; abstr 3503). Roh M, Yothers G, O’Connell M, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol. 2011. J Clin Oncol 29:2011 (suppl; abstr 3503).
60.
Zurück zum Zitat Roedel C, Becker H, Fietkau R, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: first results of the German CAO/ARO/AIO-04 randomized phase III trial. J Clin Oncol. 29:2011 (suppl; abstr LBA3505) 2011. Roedel C, Becker H, Fietkau R, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: first results of the German CAO/ARO/AIO-04 randomized phase III trial. J Clin Oncol. 29:2011 (suppl; abstr LBA3505) 2011.
61.
Zurück zum Zitat Navarro M, et al. A phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006;66(1):201–5.PubMedCrossRef Navarro M, et al. A phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006;66(1):201–5.PubMedCrossRef
62.
Zurück zum Zitat Willeke F, et al. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer. 2007;96(6):912–7.PubMedCrossRef Willeke F, et al. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer. 2007;96(6):912–7.PubMedCrossRef
63.
Zurück zum Zitat Klautke G, et al. Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. Br J Cancer. 2005;92(7):1215–20.PubMedCrossRef Klautke G, et al. Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. Br J Cancer. 2005;92(7):1215–20.PubMedCrossRef
64.
Zurück zum Zitat Mitchell EP. Irinotecan in preoperative combined-modality therapy for locally advanced rectal cancer. Oncology (Williston Park). 2000;14(12 Suppl 14):56–9. Mitchell EP. Irinotecan in preoperative combined-modality therapy for locally advanced rectal cancer. Oncology (Williston Park). 2000;14(12 Suppl 14):56–9.
65.
Zurück zum Zitat Willeke F, Horisberger K, Post S. Neoadjuvant treatment of rectal cancer: towards an individualised therapy. Z Gastroenterol. 2006;44(10):1053–63.PubMedCrossRef Willeke F, Horisberger K, Post S. Neoadjuvant treatment of rectal cancer: towards an individualised therapy. Z Gastroenterol. 2006;44(10):1053–63.PubMedCrossRef
66.
Zurück zum Zitat Glynne-Jones R, et al. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study. Br J Cancer. 2007;96(4):551–8.PubMedCrossRef Glynne-Jones R, et al. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study. Br J Cancer. 2007;96(4):551–8.PubMedCrossRef
67.
Zurück zum Zitat Chung KY, Minsky B, Schrag D, O’Reilly D, D’Adamo E, Hollywood M, et al. Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-Fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer. J Clin Oncol. 2006;24(18s):Abstract 3560. Chung KY, Minsky B, Schrag D, O’Reilly D, D’Adamo E, Hollywood M, et al. Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-Fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer. J Clin Oncol. 2006;24(18s):Abstract 3560.
68.
Zurück zum Zitat Machiels JP, et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol. 2007;18(4):738–44.PubMedCrossRef Machiels JP, et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol. 2007;18(4):738–44.PubMedCrossRef
69.
Zurück zum Zitat Rodel C, et al. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys. 2008;70(4):1081–6.PubMedCrossRef Rodel C, et al. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys. 2008;70(4):1081–6.PubMedCrossRef
70.
Zurück zum Zitat Hofheinz RD, et al. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2006;66(5):1384–90.PubMedCrossRef Hofheinz RD, et al. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2006;66(5):1384–90.PubMedCrossRef
71.
Zurück zum Zitat Horisberger K, et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. Int J Radiat Oncol Biol Phys. 2009;74(5):1487–93.PubMedCrossRef Horisberger K, et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. Int J Radiat Oncol Biol Phys. 2009;74(5):1487–93.PubMedCrossRef
72.
Zurück zum Zitat Bertolini F, et al. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2009;73(2):466–72.PubMedCrossRef Bertolini F, et al. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2009;73(2):466–72.PubMedCrossRef
73.
Zurück zum Zitat Eisterer WM, De Vries A, Oefner D, Greil R, Rabl H, Tschmelitsch J, et al. Neoadjuvant chemoradiation therapy with capecitabine plus cetuximab and external beam radiotherapy in locally advanced rectal cancer (LARC). J Clin Oncol. 2009;27(15s):Abstract 4109. Eisterer WM, De Vries A, Oefner D, Greil R, Rabl H, Tschmelitsch J, et al. Neoadjuvant chemoradiation therapy with capecitabine plus cetuximab and external beam radiotherapy in locally advanced rectal cancer (LARC). J Clin Oncol. 2009;27(15s):Abstract 4109.
74.
Zurück zum Zitat Velenik V, et al. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol. 2010;36(3):244–50.PubMedCrossRef Velenik V, et al. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol. 2010;36(3):244–50.PubMedCrossRef
75.
Zurück zum Zitat Glynne-Jones R, Mawdsley S, Harrison M. Cetuximab and chemoradiation for rectal cancer–is the water getting muddy? Acta Oncol. 2010;49(3):278–86.PubMedCrossRef Glynne-Jones R, Mawdsley S, Harrison M. Cetuximab and chemoradiation for rectal cancer–is the water getting muddy? Acta Oncol. 2010;49(3):278–86.PubMedCrossRef
76.
Zurück zum Zitat Crane CH, et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010;76(3):824–30.PubMedCrossRef Crane CH, et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010;76(3):824–30.PubMedCrossRef
77.
Zurück zum Zitat Chua YJ, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 2010;11(3):241–8.PubMedCrossRef Chua YJ, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 2010;11(3):241–8.PubMedCrossRef
78.
Zurück zum Zitat Dewdney A, Cunningham D, Capdevila J, et al. EXPERT-C: a randomized phase II European multicentre trial of neoadjuvant capecitabine/oxaliplatin chemotherapy and chemoradiation with or without cetuximab followed by total mesorectal excision in patients with MRI-defined high-risk rectal cancer. J Clin Oncol. 2011. J Clin Oncol 29: 2011 (suppl; abstr 3513). Dewdney A, Cunningham D, Capdevila J, et al. EXPERT-C: a randomized phase II European multicentre trial of neoadjuvant capecitabine/oxaliplatin chemotherapy and chemoradiation with or without cetuximab followed by total mesorectal excision in patients with MRI-defined high-risk rectal cancer. J Clin Oncol. 2011. J Clin Oncol 29: 2011 (suppl; abstr 3513).
79.
Zurück zum Zitat • Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006;333(7572):779. Demonstrated that MRI can accurately predict a threatened or potentially involved CRM. • Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006;333(7572):779. Demonstrated that MRI can accurately predict a threatened or potentially involved CRM.
80.
Zurück zum Zitat Patel UB, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 2011. Patel UB, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 2011.
81.
Zurück zum Zitat Denecke T, et al. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging? Eur Radiol. 2005;15(8):1658–66.PubMedCrossRef Denecke T, et al. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging? Eur Radiol. 2005;15(8):1658–66.PubMedCrossRef
82.
Zurück zum Zitat Calvo FA, et al. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys. 2004;58(2):528–35.PubMedCrossRef Calvo FA, et al. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys. 2004;58(2):528–35.PubMedCrossRef
83.
Zurück zum Zitat Guillem JG, et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg. 2004;199(1):1–7.PubMedCrossRef Guillem JG, et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg. 2004;199(1):1–7.PubMedCrossRef
84.
Zurück zum Zitat Kalff V, et al. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med. 2006;47(1):14–22.PubMed Kalff V, et al. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med. 2006;47(1):14–22.PubMed
85.
Zurück zum Zitat Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2009;74(3):673–88.PubMedCrossRef Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2009;74(3):673–88.PubMedCrossRef
86.
Zurück zum Zitat Rebischung C, et al. Prognostic value of P53 mutations in rectal carcinoma. Int J Cancer. 2002;100(2):131–5.PubMedCrossRef Rebischung C, et al. Prognostic value of P53 mutations in rectal carcinoma. Int J Cancer. 2002;100(2):131–5.PubMedCrossRef
87.
Zurück zum Zitat Amado RG, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626–34.PubMedCrossRef Amado RG, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626–34.PubMedCrossRef
88.
Zurück zum Zitat De Roock W, et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011;12(6):594–603.PubMedCrossRef De Roock W, et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011;12(6):594–603.PubMedCrossRef
89.
Zurück zum Zitat Gerard JP, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620–5.PubMedCrossRef Gerard JP, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620–5.PubMedCrossRef
Metadaten
Titel
Toward the Non-surgical Management of Locally Advanced Rectal Cancer
verfasst von
Alice Dewdney
David Cunningham
Publikationsdatum
01.06.2012
Verlag
Current Science Inc.
Erschienen in
Current Oncology Reports / Ausgabe 3/2012
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-012-0234-z

Weitere Artikel der Ausgabe 3/2012

Current Oncology Reports 3/2012 Zur Ausgabe

Genitourinary Cancers (E Jonasch, Section Editor)

Renal Cell Carcinoma Deep Sequencing: Recent Developments

Gastrointestinal Cancers (L Saltz, Section Editor)

Management of Hepatocellular Carcinoma: Beyond Sorafenib

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.